CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
Year-over-year earnings per share growth rate
Latest
-88.89%
↑ 58% vs avg
Percentile
P18
Within normal range
Streak
1 qtr
Consecutive growthAccelerating
Average
-213.42%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -88.89% |
| Q3 2025 | -7400.00% |
| Q2 2025 | -100.44% |
| Q1 2025 | 12.50% |
| Q4 2024 | 256.08% |
| Q3 2024 | 187.53% |
| Q2 2024 | -145.29% |
| Q1 2024 | 1270.97% |
| Q4 2023 | -66.58% |
| Q3 2023 | 327.61% |
| Q2 2023 | -11.64% |
| Q1 2023 | 96.35% |
| Q4 2022 | -17.65% |
| Q3 2022 | 5.56% |
| Q2 2022 | 0.00% |
| Q1 2022 | 10.00% |
| Q4 2021 | -14.29% |
| Q3 2021 | -16.67% |
| Q2 2021 | -15.38% |
| Q1 2021 | 18.75% |
| Q4 2020 | 0.00% |
| Q3 2020 | 5.88% |
| Q2 2020 | -225.93% |
| Q1 2020 | 134.62% |
| Q4 2019 | -50.00% |
| Q3 2019 | 18.75% |
| Q2 2019 | -106.45% |
| Q1 2019 | 56.94% |
| Q4 2018 | -35.85% |
| Q3 2018 | -51.43% |
| Q2 2018 | 12.50% |
| Q1 2018 | -2584.47% |
| Q4 2017 | 105.75% |
| Q3 2017 | 59.42% |
| Q2 2017 | -200.00% |
| Q1 2017 | 41.03% |
| Q4 2016 | 2.50% |
| Q3 2016 | -2.56% |
| Q2 2016 | 11.36% |
| Q1 2016 | -37.50% |